Market Overview

Kevin Kelly's Allergan Trade

Related AGN
Allergan's Strength Lies In Its New Products And Robust Pipeline
Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock
Biotech Forum Daily Digest: Biotech Has Tough Week; Will Conference Buoy Immunotherapy Concerns? (Seeking Alpha)

Kevin Kelly of Recon Capital Partners shared with the viewers of Bloomberg Markets his options trade in Allergan plc Ordinary Shares (NYSE: AGN).

The stock is trading more than 25 percent lower year-to-date and Kelly thinks there is a lot of uncertainty in the market right now. He is concerned about a possible impact of the presidential election on the market and there is also the risk associated with the earnings season. The company is going to report earnings on November 2 and Kelly wants to use a stock replacement strategy to reduce the risk.

He thinks it would be a good idea to sell the stock and buy the January 230 call for $12.80. The most he can lose is $12.80 and the break even for the trade is at $242.80 or 6.5 percent higher.

Posted-In: Bloomberg Markets Kevin KellyCNBC Options Markets Media


Related Articles (AGN)

View Comments and Join the Discussion!